Aluminum adjuvant with pseudo-boehmite structure and preparation method thereof
By reacting at 55-65°C and shearing the aluminum alkoxide and water at high speed, an aluminum adjuvant with a pseudo-boehmite structure was prepared, which solved the long-term high temperature and acid addition of the aluminum adjuvant preparation process in the prior art. The difficulty of achieving rapid and safe preparation and higher cellular immunity effects.
Patent Information
- Application Number
- CN202210373841.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-04-11
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2042-04-11
AI Technical Summary
The existing aluminum adjuvant preparation methods require long-term high-temperature hydrothermal treatment and acid-added treatment, which have problems of preparation difficulties and safety hazards.
The aluminum alkoxide was used to react with water at a condition of 55 to 65°C, and high-speed shear was performed at a rate of 8000 to 15000 rpm to obtain an aluminum adjuvant with a pseudoboehmite structure, avoiding additional acid addition and hydrothermal treatment.
The rapid preparation of aluminum adjuvant is achieved, with faster protein adsorption speed and higher protein adsorption amount, and the uniformity and stability of the product are ensured in vaccine production, and a higher cellular immunity level is induced.
Smart Images

Figure CN114870007B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to an aluminum adjuvant with a pseudo-boehmite structure and a preparation method thereof. Background Art
[0002] Aluminum adjuvants have a history of nearly a hundred years of use since they were first licensed for use in vaccines in 1926. As the most widely used and most vaccinated vaccine adjuvant in history, it has shown good safety and effectiveness. It is generally believed that aluminum adjuvants can effectively adhere to antigens, exert a depot effect after entering the body, and slowly release antigens for long-lasting stimulation; at the same time, it can aggregate free antigens into particles, thereby improving the efficiency of antigen uptake by antigen-presenting cells (Marrack, P., AS Mckee, and MW Munks. "Towards an understanding of the adjuvant action of aluminium." Nature Reviews Immunology 9.4 (2009): 287-293.); protect antigens from degradation and improve antigen stability (Colaprico, A., et al. "Adsorption onto aluminum hydroxide adjuvant protects antigens from degradation." Vaccine 38.19 (2020).); activate NLRP3 inflammasome, caspase-1 and other cellular targets, induce cells to produce danger signals, and thus promote the secretion of cytokines such as IL-1β and IL-18.
[0003] However, aluminum adjuvants also have their application limitations: although they can induce strong humoral immunity and produce antibodies to neutralize pathogens, they lack cellular immune stimulation and are difficult to eliminate pathogens that enter cells, which is crucial for the prevention of some diseases (such as AIDS, malaria, etc.).
[0004] In order to improve the stimulating effect of aluminum adjuvant on cellular immunity, a common method is to combine aluminum adjuvant with immune stimulants (such as TLR agonists): for example, 50 μg 3-O-deacyl-4'-monophosphoryl lipid A (MPLA) adsorbed on 500 μg aluminum adjuvant to obtain adjuvant AS04, which can stimulate cross-protection when used for HPV vaccine. Patents with publication numbers CN113304257A and CN113521273A both use aluminum adjuvant and CpG as adjuvants for inactivated COVID-19 vaccines, and patents with publication number CN112220920A use aluminum adjuvant and CpG as adjuvants for recombinant COVID-19 protein vaccines. Patents with patent number CN112138155 A use aluminum adjuvant and CpG mixed for recombinant shingles vaccines, and patents with publication number CN111920946A use aluminum mixed with STING agonists as adjuvants for recombinant COVID-19 protein vaccines. Another way to make up for this is to reduce the particle size of the aluminum adjuvant so that it can enter the lymph nodes richer in CD8 lymphocytes, thereby directly stimulating CD8, which can theoretically improve the level of cellular immunity (Theodora Fifis, Anita Gamvrellis, et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol. 2004 (173): 3148-3154.). Patent publication number CN104587464A discloses a vaccine carrier based on aluminum hydroxide nanoparticles. As a delivery carrier, it can be combined with the immune stimulant CpG better than the traditional aluminum adjuvant combined with CpG. Because it can effectively target lymph nodes, it can better stimulate immune cells, thereby inducing a stronger cellular immune effect.
[0005] Commonly used aluminum adjuvants include aluminum hydroxide and aluminum phosphate, and the preparation methods are similar: by mixing two substances to form a precipitate. For example, when preparing aluminum hydroxide, aluminum salts (such as aluminum chloride, aluminum sulfate, aluminum nitrate, etc.) are mixed with alkaline solutions (such as sodium hydroxide, potassium hydroxide, urea, etc.) to react and form a precipitate. Aluminum hydroxide adjuvants with different forms are prepared by controlling the initial concentration of salt, the pH value of the reaction solution, the stirring speed, the reaction temperature, etc. in the process. For example, the method published in patent CN 108066759 A uses sodium chloride solution to add potassium aluminum sulfate and drip sodium hydroxide to prepare; the method published in patent CN 112569350 A is similar to adding aluminum chloride to a salt solution, and then dripping sodium hydroxide, and controlling the pH value of the end point solution to obtain aluminum adjuvants with different crystalline structures; patent CN 113559255 A obtains aluminum hydroxide adjuvant by adding aluminum chloride solution to ammonia solution in the form of spray.
[0006] Pseudo-boehmite is a crystalline form of aluminum with the chemical formula AlOOH. It has an amorphous or irregular crystal structure and has a larger specific surface area than traditional aluminum hydroxide adjuvants, which means that it may have better adsorption capacity when mixed with antigens. It has a similar XRD diffraction pattern compared to boehmite, the precursor raw material used in the industry to prepare aluminum oxide, but the diffraction peak of pseudo-boehmite is wider than that of boehmite. In addition, the difference between the two is that pseudo-boehmite is the difference in crystal integrity, water content, and specific surface area. Pseudo-boehmite can be regarded as poorly crystallized boehmite. The Alhydrogel aluminum adjuvant produced by Croda UK is used as the gold standard for aluminum adjuvants, which has a pseudo-boehmite crystal structure. Patent CN112569350 A discloses a method for producing an aluminum adjuvant that claims to have a pseudo-boehmite structure, but by comparing the XRD diagram reported in the literature with the XRD diagram in the patent, the patent does not obtain pseudo-boehmite.
[0007] The preparation methods of boehmite include electrochemical method (ZHANG L, CHENG B, SHI WS, et al. In-situ electrochemical synthesis of 1-dimensional alumina nanostructures [J]. Mater. Chem, 2005 (15): 4889-4893.), vapor precipitation method (PROOST J, Van BOXEL S. Large-scale synthesis of high purity, one-dimensional α-Al2O3 structures [J]. Mater Chem, 2004 (14): 3058-3062.), microemulsion method (GHOSH S, NASKAR M K. Synthesis of mesoporous γ-aluminan nanorods using a double surfactant system by reverse microemulsion process [J]. RSC Advances, 2013 (3): 4207-4211.), hydrothermal method (VITORINO N, KOVALEVSKY AV, ABRANTES JCC, et al. al.Hydrothermal synthesis of boehmite in cellular aluminamonoliths for catalytic and separation applications[J].Journal of theEuropean Ceramic Society,2015(35):3119-3125.), etc., by using different methods, boehmite with different morphologies (such as granular, fibrous, lamellar, hollow spherical) can be prepared. Among them, the hydrothermal method is widely used because of its easy control of reaction conditions and easy adjustment of crystal morphology. However, the hydrothermal method often requires a long hydrothermal treatment time. For example, using AlCl 3As raw material, ethylene glycol is solvent, and it needs to be treated at 200°C for 6 hours (Ma, MG, and JFZhu. "A facilesolvothermal route to synthesis ofγ-alumina with bundle-like and flower-like morphologies." Materials Letters 63.11 (2009): 881-883.) to have pseudo-boehmite crystal form. The alcohol aluminum is hydrolyzed by the usual method, and then dried to obtain boehmite, which can be used as a raw material for aluminum adjuvant. However, this particle cannot form a sol in water. In order to promote its dissolution, a strong acid solution must be added. There are certain risks in using it as a vaccine adjuvant. Meanwhile, the prior art method of preparing aluminum adjuvants by hydrolysis of aluminum alcohol often requires a relatively high temperature and a long treatment time (Masood, H., JL White, and SL Hem. "Relationship between protein adsorptive capacity and the X-ray diffraction pattern of aluminiumhydroxide adjuvants." Vaccine 12.2 (1994): 187-189.), which brings difficulties to the preparation. Therefore, it is urgent to find a new method for preparing aluminum adjuvants to solve the above problems. Summary of the invention
[0008] One aspect of the present invention is to provide a new aluminum adjuvant with a pseudo-boehmite structure and a preparation method thereof in view of the defects of the prior art method of preparing aluminum adjuvant by hydrolysis of alcohol aluminum, which requires long-term high-temperature hydrothermal treatment and the addition of acid to form the final product.
[0009] The technical solution provided by the present invention is:
[0010] A method for preparing an aluminum adjuvant with a pseudo-boehmite structure comprises reacting aluminum alkoxide with water at 55-65° C., and homogenizing the suspension obtained by the reaction after high-speed shearing at a rate of 8000-15000 rpm to obtain the aluminum adjuvant.
[0011] In the present invention, the chemical formula of the aluminum alkoxide is Al(OR) n When it reacts completely with water, it hydrolyzes to form oxides and / or oxide water and precipitation. Preferably, in one embodiment of the present invention, n=3, R=C 3 H 7 The aluminum alkoxide is aluminum isopropoxide, and its chemical formula is Al(C 3 H7 O) 3 .
[0012] In certain embodiments of the present invention, the reaction temperature of aluminum alkoxide and water can be 55°C, 56°C, 57°C, 58°C, 59°C, or 60°C. Preferably, in one embodiment of the present invention, the reaction temperature is 60°C, and the reaction time is 3 to 5 hours.
[0013] In one embodiment of the present invention, the above reaction is carried out by slowly adding water to the aluminum alkoxide and reacting under slow stirring, so that the gas generated by the reaction can be volatilized quickly. In industrial production, a reactor with a stirring exhaust device can also be used for the reaction.
[0014] In the present invention, after the above reaction is completed, a water-soluble colloidal solution is generated, which can be directly used for the preparation of adjuvants without the need for additional acid addition, hydrothermal treatment, etc.
[0015] In certain embodiments of the present invention, after the reaction of the aluminum alkoxide and water is completed, a step of washing the suspension obtained by the reaction may be further included. Specifically, for example:
[0016] Stir for 3 to 5 hours, then stop stirring. Allow to settle until the white insoluble matter is completely precipitated, and then discard the upper layer of liquid. Inject 500 ml of injection water again, resuspend, and continue to allow to settle naturally until the white insoluble matter is completely precipitated, clarify, and discard the upper layer of liquid. Repeat this process twice. Then inject 1000 ml of injection water to resuspend.
[0017] Preferably, in certain embodiments of the present invention, the high-speed shearing time is 10 to 15 minutes. More preferably, in one embodiment of the present invention, the high-speed shearing time is 10 minutes. The high-speed shearing can be performed in a high-speed shearing emulsifier.
[0018] Preferably, in certain embodiments of the present invention, the mass ratio of the aluminum alkoxide to water is 1:10 to 20. For example, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, 1:20. Preferably, in one embodiment of the present invention, the mass ratio of the aluminum alkoxide to water is 1:10.
[0019] In certain embodiments of the present invention, the homogenization method may be high pressure homogenization, hydraulic ultrafine homogenization, super field wave homogenization or shear homogenization. Preferably, in certain embodiments of the present invention, the homogenization method is high pressure homogenization, and the pressure of the high pressure homogenization is 500 bar to 2000 bar. The homogenization may be performed in a homogenization device, for example, a high pressure homogenizer.
[0020] In order to remove bacteria in the product, in certain embodiments of the present invention, after the above steps are completed, a sterilization process for the product may be further included, for example, high-temperature sterilization of the product at 120° C. for 30 minutes.
[0021] Another aspect of the present invention provides an aluminum adjuvant, which is prepared by the above-mentioned preparation method.
[0022] Preferably, in certain embodiments of the present invention, the diffraction angle 2θ of the powder X-ray diffraction of the aluminum adjuvant has a characteristic peak near 14.14 degrees, the particle size of the aluminum adjuvant is 426.0±34.08 nm, and the zeta potential of the aluminum adjuvant is 35.6±1.41 mV.
[0023] Preferably, in one embodiment of the present invention, the solvent of the aluminum adjuvant is water.
[0024] Another aspect of the present invention provides a vaccine, which comprises the above-mentioned aluminum adjuvant.
[0025] Preferably, in one embodiment of the present invention, the antigen of the above-mentioned vaccine is hepatitis B surface antigen.
[0026] The beneficial effects of the present invention are:
[0027] 1) The preparation method of the aluminum adjuvant of the present invention uses only two raw materials, water and aluminum isopropoxide, and does not require baking or acid dissolution. The final product is a colloidal solution in a water-soluble state. At the same time, the method of the present invention has the advantages of low reaction temperature, short time and simple process.
[0028] 2) The aluminum adjuvant of the present invention has a faster protein adsorption rate and a higher protein adsorption amount than the aluminum adjuvant prepared by a simple precipitation method.
[0029] 3) The aluminum adjuvant of the present invention as a vaccine adjuvant can induce a higher cellular immunity level on the basis of inducing the same strength of humoral immunity level compared with the aluminum adjuvant prepared by the conventional precipitation method and the commercially available aluminum adjuvant with pseudo-boehmite characteristics.
[0030] 4) If the aluminum adjuvant is not easy to disperse or has poor suspension stability during the vaccine preparation process, it needs to be re-homogenized. If it settles too quickly during the packaging process, it is also easy to affect the uniformity of the product. The aluminum adjuvant in the present invention has excellent suspension stability, is easy to disperse, and has a fluffy structure, which ensures that a product with better uniformity is obtained during the vaccine production and application process. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1The figure is a comparison diagram of the state of the aluminum adjuvants prepared in Example 1 of the present invention and Comparative Examples 1 and 2 after being placed for 24 hours, wherein the upper left is the state of Comparative Example 1 after being placed for 0 hours, the upper right is the state of Example 1 after being placed for 0 hours, the lower left is the state of Comparative Example 1 after being placed for 24 hours, and the lower right is the state of Example 1 after being placed for 24 hours;
[0032] Figure 2 This is the XRD result diagram of the aluminum adjuvant prepared in Example 1 of the present invention;
[0033] Figure 3 The XRD results of the aluminum adjuvants prepared in Comparative Examples 1 and 2 of the present invention are shown in Figure 1, wherein A is the XRD result of the aluminum adjuvant prepared in Comparative Example 1, and B is the XRD result of the aluminum adjuvant prepared in Comparative Example 2;
[0034] Figure 4 The XRD result diagrams of the aluminum adjuvants prepared in Comparative Example 3 of the present invention and two other commercially available aluminum adjuvants, wherein A is the XRD result diagram of the aluminum adjuvant prepared in Comparative Example 3, B is the XRD result diagram of the Alhydrogel aluminum adjuvant, and C is the XRD result diagram of the SERVA aluminum adjuvant;
[0035] Figure 5 is a scanning electron microscope image of the aluminum adjuvant prepared in the embodiment of the present invention;
[0036] Figure 6 The graphs are comparative results of the adsorption effects of the aluminum adjuvants prepared in Example 1 and Comparative Example 3 of the present invention and two other commercially available aluminum adjuvants on proteins, wherein A is the result graph of the green fluorescent protein clover, and B is the result graph of the red fluorescent protein mRuby;
[0037] Figure 7 It is a curve diagram of the adsorption rate of protein by aluminum adjuvants prepared in Example 1 and Comparative Example 3 of the present invention and two other commercially available aluminum adjuvants;
[0038] Figure 8 The figure is a comparison result of the sedimentation test of the aluminum adjuvants prepared in Example 1 and Comparative Example 3 of the present invention and two other commercially available aluminum adjuvants, wherein the upper row is the state of being placed for 0 minutes, and the lower row is the state of being placed for 120 minutes. The test tubes from left to right are the aluminum adjuvant (Hydrolysis) prepared in Example 1, Alhydrogel, Serva, and the aluminum adjuvant (precipitation) prepared in Comparative Example 3;
[0039] Fig. 9 The graph is a result of the suspension stability index of the aluminum adjuvants prepared in Example 1 and Comparative Example 3 of the present invention and two other commercially available aluminum adjuvants;
[0040] Fig.10The antibody titers after immunization with HBsAg adsorbed by aluminum adjuvants prepared in Example 1 and Comparative Example 3 of the present invention and two other commercially available adjuvants, wherein A is the antibody titer result diagram after 2 doses of immunization, and B is the antibody titer result diagram after 3 doses of immunization;
[0041] Fig.11 The result graph is a graph showing the number of antigen-specific IFN-γ secreting cells after immunization with HBsAg adsorbed by aluminum adjuvants prepared in Example 1 and Comparative Example 3 of the present invention and two other commercially available adjuvants;
[0042] Fig.12 This is a graph showing the results of the number of antigen-specific IFN-γ secreting cells after immunization with the same amount of HBsAg adsorbed by the aluminum adjuvants (different doses) prepared in Comparative Example 3 and Example 1 of the present invention. DETAILED DESCRIPTION
[0043] The present invention discloses an aluminum adjuvant having a pseudo-boehmite structure and a preparation method thereof. Those skilled in the art can refer to the contents of this article and appropriately improve the process parameters to achieve the same. It should be particularly pointed out that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention, and relevant personnel can obviously modify or appropriately change and combine the contents described herein without departing from the content, spirit and scope of the present invention to achieve and apply the technology of the present invention.
[0044] In the present invention, unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Unless otherwise expressly indicated, throughout the specification and claims, the term "including" or its variations such as "comprising" or "including" etc. will be understood to include the stated elements or components without excluding other elements or other components. The terms "such as", "for example", etc. are intended to refer to exemplary embodiments and are not intended to limit the scope of the present disclosure.
[0045] Some of the terms used in the present invention are explained below.
[0046] The term "adjuvant", also known as immune adjuvant, refers to a class of substances that are injected together with antigens or injected in advance to increase the body's immune response to antigens or change the type of response. The effects of immune adjuvants include: 1. enhancing the antigenicity of weak antigenic substances; 2. increasing the level of specific circulating antibodies, or producing effective protective immunity; 3. changing the type of circulating antibodies produced; 4. enhancing the ability of cell-mediated hypersensitivity reactions; 5. protecting antigens (especially DNA and RNA) from being decomposed by enzymes in the body. Adjuvants can especially enhance the specific response of certain small molecular weight polysaccharides or polypeptides with weak antigenicity.
[0047] The term "aluminum adjuvant" is the most widely used immune adjuvant at present. There are mainly two types of aluminum hydroxide and aluminum phosphate, among which aluminum hydroxide is more widely used. It is currently believed that the vaccine adjuvant effect mechanism of aluminum adjuvant mainly includes "depot effect" and "immune stimulation effect". Although conventional aluminum adjuvants can enhance humoral immune response, it is often difficult to effectively induce cellular immune response. In addition, aluminum adjuvants can also induce Ig E-mediated type I hypersensitivity reactions.
[0048] The term "pseudo-boehmite structure" refers to a crystalline form of hydrated aluminum oxide, which has incomplete crystallization but a fluffy structure and a large specific surface area.
[0049] The term "homogenization" refers to the process of breaking up the solid particles in the liquid material to make the solid particles ultra-fine and form a uniform suspended emulsion. High-pressure homogenization technology is a process in which the material undergoes a series of changes in physical, chemical, and structural properties under high pressure to ultimately achieve a homogenization effect.
[0050] The term "aluminum isopropoxide" refers to aluminum isopropoxide, and the molecular formula is generally written as Al(Oi-Pr) 3 , where i-Pr represents isopropyl (—CH(CH 3 ) 2 ). Aluminum isopropoxide is a colorless solid and is a very important reagent in organic synthesis. Its structure is very complex and is closely related to factors such as solvents.
[0051] In order to enable those skilled in the art to better understand the technical solution of the present invention, the present invention is further described in detail below in conjunction with specific embodiments.
[0052] Example 1: Preparation of aluminum adjuvant
[0053] Step 1) Weigh 50 g of aluminum isopropoxide, add it into a dry-baked glass beaker, slowly inject 500 ml of water for injection, slowly stir, heat to 60° C. to accelerate the volatilization of isopropanol produced by the hydrolysis of aluminum isopropoxide, and continue to stir slowly.
[0054] Step 2) Washing: Stir for 3-5 hours, stop stirring. Let it stand to clarify until the white insoluble matter is completely precipitated, and pour off the upper liquid; inject 500 ml of injection water again, resuspend and continue to stand naturally until the white insoluble matter is completely precipitated, clarify, pour off the upper liquid, repeat 2 times. Then inject 1000 ml of injection water to resuspend.
[0055] Step 3) Homogenization: high-speed shearing at 10000 rpm for 10 min, followed by high-pressure homogenization.
[0056] Step 4) Sterilization: high temperature sterilization at 120°C for 30 min.
[0057] Example 2: Preparation of aluminum adjuvant
[0058] Step 1) Weigh 50 g of aluminum isopropoxide, add it into a dry-baked glass beaker, slowly inject 1000 ml of water for injection, slowly stir, heat to 55° C. to accelerate the volatilization of isopropanol produced by the hydrolysis of aluminum isopropoxide, and continue to stir slowly.
[0059] Step 2) Washing: Stir for 3-5 hours, stop stirring. Let it stand to clarify until the white insoluble matter is completely precipitated, and pour off the upper liquid; inject 500 ml of injection water again, resuspend and continue to stand naturally until the white insoluble matter is completely precipitated, clarify, pour off the upper liquid, repeat 2 times. Then inject 1000 ml of injection water to resuspend.
[0060] Step 3) Homogenization: high-speed shearing at 15000 rpm for 15 min, followed by high-pressure homogenization.
[0061] Step 4) Sterilization: high temperature sterilization at 120°C for 30 min.
[0062] Example 3: Preparation of aluminum adjuvant
[0063] Step 1) Weigh 50 g of aluminum isopropoxide, add it into a dry-baked glass beaker, slowly inject 500 ml of water for injection, slowly stir, heat to 60° C. to accelerate the volatilization of isopropanol produced by the hydrolysis of aluminum isopropoxide, and continue to stir slowly.
[0064] Step 2) Washing: Stir for 3-5 hours, stop stirring. Let it stand to clarify until the white insoluble matter is completely precipitated, and pour off the upper liquid; inject 500 ml of injection water again, resuspend and continue to stand naturally until the white insoluble matter is completely precipitated, clarify, pour off the upper liquid, repeat 2 times. Then inject 1000 ml of injection water to resuspend.
[0065] Step 3) Homogenization: high-speed shearing at 8000 rpm for 15 min, followed by high-pressure homogenization.
[0066] Step 4) Sterilization: high temperature sterilization at 120°C for 30 min.
[0067] Comparative Example 1: Preparation of aluminum adjuvant
[0068] Aluminum adjuvant was prepared by the same method as in Example 1, except that step 2) panning and step 3) homogenization were not included.
[0069] Comparative Example 2: Preparation of aluminum adjuvant
[0070] Aluminum adjuvant was prepared by the same method as in Example 1, except that step 3) the homogenization step was not included.
[0071] Observe the final products obtained in Example 1, Comparative Example 1 and Comparative Example 2. Figure 1As shown, it can be found that the products obtained in Comparative Example 1 and Comparative Example 2 are similar, both are turbid liquids, and particles can be observed to sink quickly after standing, while the product obtained in Example 1 is a translucent colloidal liquid, and no obvious sedimentation is observed after long-term standing without dilution.
[0072] X-ray diffraction (XRD) analysis was performed on the three at the same time, such as Figure 2 , 3 As shown, each product exhibits a diffraction peak characteristic of pseudo-boehmite. Comparison of the (020) diffraction peak position 2θ(020) shows that the intermediate product of Comparative Example 1 is 13.54°, the product of Comparative Example 2 is 13.86°, and the product of Example 1 is 14.14°. The (020) diffraction peaks of the three gradually increase (Comparative Example 1: 204, Comparative Example 2: 226; Example 1: 270). By comparison, it can be seen that the product obtained in Example 1 has the best crystallinity. Compared with the conventional boehmite preparation which requires a higher hydrothermal temperature and an extraordinary hydrothermal time, after high-pressure homogenization, a pseudo-boehmite aluminum adjuvant with a very good colloidal state can be obtained by conventional sterilization (120°C, 30min).
[0073] Comparative Example 3: Preparation of aluminum adjuvant by traditional precipitation method
[0074] Aluminum chloride (AlCl) with an aluminum ion content of 0.25M 3 ) solution, add 200ml into a dry-baked glass beaker and stir. Use a peristaltic pump to slowly add a 0.25M sodium hydroxide solution while monitoring the pH. When the pH reaches about 5, start adding the aluminum salt solution at the same time. Adjust the dropping speed of the two solutions to keep the pH constant at about 5, and continue adding for 1 hour. After centrifugation, the precipitate is washed twice with 0.3% sodium chloride solution, and then dissolved again with 0.3% sodium chloride solution. After determining the aluminum content using an inductively coupled plasma mass spectrometer (ICP-MS), dilute it with 0.3% sodium chloride solution to an aluminum content of 0.5mg / ml.
[0075] Experimental Example 1: Particle size and zeta potential detection
[0076] Aluminum adjuvant (denoted as Hydrolysis) was prepared using the method in Example 1. Then, the aluminum content was determined using an inductively coupled plasma mass spectrometer (ICP-MS). Water was diluted to an aluminum content of 0.5 mg / ml, and the particle size and zeta potential were determined using a Malvern ZetasizerNano ZS90 laser particle size analyzer. Two commercially available aluminum adjuvants (denoted as Alhydrogel and SERVA) and the aluminum adjuvant prepared by the traditional precipitation method in Comparative Example 3 (denoted as Precipitation) were analyzed simultaneously. The results are shown in Table 1.
[0077] Table 1 Potential values, conductivity and particle size values of various aluminum adjuvants
[0078] Aluminum adjuvant Zeta potential(mV) con(mS / cm) size(nm) PdI Alhydrogel 10.6±0.354 0.0185±0.00318 1260±77.07 0.058±0.080 SERVA 12.6±0.283 0.0304±0 1592±32.53 0.065±0.011 precipitation 10.1±0.233 4.81±0.870 12980±289.9 0.395±0.006 Hydrolysis 35.6±1.41 0.0017±0 426.0±34.08 0.489±0.056
[0079] The analysis results show that the aluminum adjuvant prepared in Example 1 has a smaller particle size and a zeta potential greater than the other three aluminum adjuvants. At the same time, since the solution used in the adjuvant is only water, the aluminum adjuvant obtained in Example 1 has extremely low conductivity, just like Alhydrogel and SERVA aluminum adjuvants. Since its solution is only water, it has little effect on the antigen when mixed with different antigens in the buffer.
[0080] Experimental Example 2: XRD measurement
[0081] Take an appropriate amount of aluminum adjuvant solution (total aluminum content is about 200 mg) in a 50 ml centrifuge tube, centrifuge at 10000g for 20 minutes, discard the upper solution, and then suspend with deionized water. Centrifuge again, discard the upper solution, suspend with water, centrifuge, and repeat washing several times. Pour out the precipitate, dry it naturally, grind it into fine powder for testing, spread it on the base sample table, ensure that the sample is flat and there is no warping, and then use an X-ray diffractometer (Shimadzu, model XRD-6100) for scanning test: Cu target, voltage 40kV, current 30mA, scanning angle 5-80°.
[0082] The results are as follows Figure 2 , 4 As shown in the results, it can be seen that, unlike the aluminum adjuvant prepared by the traditional precipitation method, the aluminum adjuvant prepared in Example 1 has similar XRD spectrum characteristics to Alhydrogel and SERVA aluminum adjuvants, showing a similar pseudo-boehmite crystal structure. However, the aluminum adjuvant (Precipitation) prepared by precipitation method without hydrothermal treatment does not have this characteristic.
[0083] Experimental Example 3: Electron Microscope Detection
[0084] After shaking the aluminum adjuvant sample prepared in Example 1 evenly, 1 mL of the stock solution was added to deionized water to make the volume 4 mL, and the diluted sample was dripped onto the aluminum foil with a pipette and dried naturally. Finally, the sample was sprayed with gold and observed using a Zeiss SIGMA 500 scanning electron microscope. The results are shown in Figure 5 As shown, the results show that the aluminum adjuvant obtained in Example 1 has a smaller particle size and a strip-shaped shape under an electron microscope.
[0085] Experimental Example 4: Adsorption of aluminum adjuvant on protein
[0086] 1) Adsorption capacity test
[0087] In order to facilitate the observation of aluminum adsorption on protein, fluorescent proteins were used for testing. Two fluorescent proteins were selected in this experimental example: green fluorescent protein clover and red fluorescent protein mRuby. The process is as follows: take 5ml0.1mg / ml aluminum adjuvant, Alhydrogel aluminum adjuvant and SERVA aluminum adjuvant prepared in Example 1 and Comparative Example 3, add 5ml 0.4mg / ml protein (clover or mRuby fluorescent protein) respectively and mix evenly, take 500μl samples at different time points, centrifuge at 12000rpm for 5min, take 200μl supernatant, and measure the protein content in the supernatant. The protein adsorption amount is the total protein amount minus the free amount. At the same time, calculate the average value of the adsorption amount after adsorption equilibrium, which is recorded as the protein adsorption amount of the aluminum adjuvant.
[0088] The results are as follows Figure 6 , as shown in Table 2. Analysis of the experimental data shows that the aluminum adjuvant rapidly adsorbs protein after mixing and reaches the equilibrium point in a short time. The aluminum adjuvant prepared in Example 1 has the same adsorption capacity for clover protein as Alhydrogel and SERVA, and is higher than the aluminum adjuvant prepared by the traditional method. The adsorption capacity for mRuby is better than that of the control aluminum adjuvant.
[0089] Table 2 Adsorption capacity of each aluminum adjuvant on fluorescent protein (clover, mRuby)
[0090]
[0091] 2) Adsorption curve drawing
[0092] Take 0.5ml 0.1mg / ml aluminum adjuvant (aluminum adjuvant prepared in Example 1 and Comparative Example 3, Alhydrogel aluminum adjuvant and SERVA aluminum adjuvant) and add 0.5ml 0.4mg / ml protein (clover or mRuby fluorescent protein) respectively and mix evenly. Use 200nm pore size filter to filter 100μl at different time points, measure the concentration of unadsorbed protein in the filtrate, and the total protein minus the unadsorbed protein is the adsorbed protein. It was found in the experiment that mRuby protein would aggregate and there would be obvious loss in filtration, so only the adsorption rate curve of aluminum adjuvant to clover protein was drawn.
[0093] The results are as follows Figure 7 As shown in the figure, it can be seen that the adsorption of protein by different aluminum adjuvants is very rapid (equilibrium can be reached in 2 minutes), and the slope of the curve represents the adsorption rate. The adsorption rate of protein by the aluminum adjuvant prepared in Example 1 is much greater than that of the aluminum adjuvant prepared in the traditional precipitation method ratio 3.
[0094] Based on the above results, it can be seen that the adsorption capacity and adsorption rate of aluminum adjuvants with pseudo-boehmite characteristics on proteins are greater than those of aluminum adjuvants without such characteristics.
[0095] Experimental Example 5: Suspension stability test
[0096] Take 4 ml of each of various aluminum adjuvants (aluminum adjuvants prepared in Example 1 and Comparative Example 3, Alhydrogel aluminum adjuvant, and SERVA aluminum adjuvant) at 0.5 mg / ml in a 15 ml centrifuge tube, add 1.5 mg of green fluorescent protein (clover) to make up the volume to 5 ml, mix evenly, and then place vertically to allow it to settle naturally. After the aluminum adjuvant adsorbs green fluorescent protein, the sedimentation of the aluminum adjuvant can be clearly seen. Observe and record, and record the volume of the adjuvant after sedimentation / total volume as the suspension stability index. The results are shown in Table 3. Figure 8 , Fig. 9 shown.
[0097] As shown in the results, if the aluminum adjuvant is not easy to disperse or has poor suspension stability during the vaccine preparation process, it needs to be re-homogenized. If it settles too quickly during the packaging process, it is also easy to affect the uniformity of the product. The aluminum adjuvant prepared in Example 1 has excellent suspension stability, is easy to disperse, and has a fluffy structure, which ensures that it obtains a product with better uniformity during the vaccine production and application process.
[0098] Table 3: Suspension stability index of each aluminum adjuvant at different time points
[0099]
[0100] Experimental Example 6: Evaluation of adjuvant effect
[0101] In order to evaluate the adjuvant effect of the aluminum adjuvant prepared in Example 1, commercially available aluminum adjuvants (Alhydrogel aluminum adjuvant and SERVA aluminum adjuvant) and aluminum adjuvants prepared by the traditional method (Comparative Example 3) were used as controls. All aluminum adjuvants used passed the endotoxin test of the horseshoe crab reagent, and the endotoxin content was ≤1EU / ml.
[0102] Twenty-five Babl / c mice aged 6 to 8 weeks were randomly divided into 5 groups. The groups are shown in Table 4.
[0103] Table 4 Immunization groups
[0104]
[0105] Three intramuscular injections were performed at 0, 2, and 4 weeks. Blood was collected at 3 and 5 weeks, and the serum was separated and the antibody titer was measured using enzyme-linked immunosorbent assay (ELISA). At the same time, the spleen of the mice was taken at 5 weeks, lymphocytes were separated, and the secretion of antigen-specific cytokines was measured using enzyme-linked immunospot (ELISPOT). The results are shown in Figure 2. Fig.10 , Fig.11 shown.
[0106] The results showed that after two injections, three different batches of aluminum adjuvants prepared in Example 1 could induce strong humoral immunity, which was better than several other aluminum adjuvants. After the third injection of booster immunization, the difference in antibody titers between the groups became smaller. At the same time, it can be seen that having a pseudo-boehmite crystal structure does not necessarily mean a better immune level. With hepatitis B surface antigen, the adjuvant obtained by traditional precipitation without hydrothermal treatment can induce a stronger humoral immunity level than the two commercially available aluminum adjuvants with pseudo-boehmite structural characteristics.
[0107] And surprisingly, the aluminum adjuvant prepared in Example 1 can induce a stronger cellular immunity level than the other aluminum adjuvants.
[0108] In order to further test the relationship between the amount of adjuvant used and the cellular immune stimulation effect of the aluminum adjuvant prepared in Example 1, three gradients of the aluminum adjuvant prepared in Example 1 were set up, and the aluminum adjuvant prepared by the traditional precipitation method (Comparative Example 3) was used as a control. Hepatitis B surface antigen was used as a model antigen for immune effect evaluation. All aluminum adjuvants used passed the endotoxin test of the horseshoe crab reagent.
[0109] Twenty-five Babl / c mice aged 6 to 8 weeks were randomly divided into 5 groups according to Table 5.
[0110] Table 5 Immunization groups
[0111]
[0112] Immunization was performed by intramuscular injection three times at 0, 2, and 4 weeks. The spleen of mice was taken at 5 weeks, lymphocytes were isolated, and the secretion of antigen-specific cytokines was measured by enzyme-linked immunospot (ELISPOT). Fig.12 shown.
[0113] The results show that the cellular immunity level induced by the aluminum adjuvant prepared by the method of Example 1 is much higher than that of the aluminum adjuvant prepared by the traditional precipitation method (Comparative Example 3), even when the adjuvant dosage is only 1 / 25 of the latter. And this stimulating effect on cellular immunity shows a certain dose correlation with the dosage of aluminum adjuvant.
[0114] Based on the above data, the aluminum adjuvant with a pseudo-boehmite structure prepared in Example 1, 2 or 3 has excellent antigen adsorption capacity, similar to other aluminum adjuvants with similar structures. At the same time, it is similar to aluminum adjuvants without this feature and can induce strong humoral immunity. The data prove that the advantages of pseudo-boehmite aluminum adjuvants are more reflected in the adsorption of proteins, while the traditional preparation of such adjuvants often requires a higher hydrothermal temperature and an ultra-long hydrothermal time. The method of the present invention improves this and has the advantages of simple preparation conditions and short time.
[0115] As the adjuvant type with the longest history of use and the most widely used, aluminum adjuvants have recognized good safety and humoral immunity induction effects, but the lack of cellular immunity induction effect has always been its shortcoming. In addition to inducing strong humoral immunity, the aluminum adjuvant obtained in this patent is particularly worth noting that this aluminum adjuvant can also induce a good cellular immunity level without adding any additional immune stimulants, which is of great significance for improving the protective effect of vaccines.
[0116] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A method for preparing an aluminum adjuvant having a pseudo-boehmite structure, characterized in that: Step 1) Weigh 50g of aluminum isopropoxide, add it into a dry-baked glass beaker, slowly inject 500ml of water for injection, slowly stir, heat to 60°C to accelerate the volatilization of isopropanol produced by the hydrolysis of aluminum isopropoxide, and continue to stir slowly; Step 2) Washing: Stir for 3-5 hours, stop stirring, let it stand to clarify until the white insoluble matter is completely precipitated, and pour off the upper liquid; inject water for injection again, resuspend and continue to stand naturally until the white insoluble matter is completely precipitated, clarify, pour off the upper liquid, repeat 2 times, and then inject water for injection to resuspend; Step 3) Homogenization: high-speed shearing at 10,000 rpm for 10 min, followed by high-pressure homogenization; Step 4) Sterilization.
2. An aluminum adjuvant, characterized in that The aluminum adjuvant is prepared by the preparation method according to claim 1, the diffraction angle 2θ of the powder X-ray diffraction of the aluminum adjuvant has a characteristic peak near 14.14 degrees, the particle size of the aluminum adjuvant is 426.0±34.08nm, and the zeta potential of the aluminum adjuvant is 35.6±1.41mV.
3. A vaccine, characterized in that The vaccine comprises the aluminum adjuvant as claimed in claim 2.
4. The vaccine according to claim 3, characterized in that The antigen of the vaccine is hepatitis B surface antigen.
Citation Information
Patent Citations
Vaccine vector based on aluminum hydoxide nano-particles
CN104587464A
Aluminum hydroxide adjuvant as well as preparation method and application thereof
CN108066759A
Cyclic dinucleotide modified aluminum nanoparticle vaccine adjuvant-delivery system and SARS-CoV-2 subunit vaccine based on same
CN111920946A
Compound adjuvant system and method for preparing adjuvant
CN112138155A
Recombinant novel coronavirus vaccine composition
CN112220920A
